K Pharma,Inc. (4896.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 810.00

From 52W high−10.69%

Volume22700.00

Market capJPY 9.31B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

JPY 810.00

From 52W high

−10.69%

Volume

22700.00

Market cap

JPY 9.31B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.4x

P/E (TTM)

—

RSI (14)

58.7

MomentumView details →

1D Return

−0.25%

YTD Return

+23.03%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−8.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

12.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−78.50%

ROA (TTM)

−33.79%

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

−17.37%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−17.34%

EBITDA YoY

—

MomentumView details →

1D Return

−0.25%

YTD Return

+23.03%

1Y Return

+20.12%

RSI (14)

58.7

vs 50D SMA

+6.28%

vs 200D SMA

+11.38%

Capital & dividendView details →

Debt/Equity

1.19x

Current Ratio

28.41x

Quick Ratio

28.29x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

−1.04B

Op. CF (TTM)

—

Next earningsNov 12, 2026 →

Latest newsMore news →

K Pharma extended its joint research agreement with National Hospital Organization Osaka Medical Center for chronic cerebral infarction regenerative medicine products until March 31, 2029.38d ago

K Pharma extended its joint research agreement with Kitasato Institute for hearing loss research until March 2027.38d ago

Similar companies

MORISHITA JINTAN CO.,LTD.4524.T KAINOS Laboratories,Inc.4556.T Carna Biosciences,Inc.4572.T WAKAMOTO PHARMACEUTICAL CO.,LTD.4512.T StemRIM Inc.4599.T Immuno-Biological Laboratories Co.,Ltd.4570.T Find similar companies →

Latest newsMore news →

K Pharma extended its joint research agreement with National Hospital Organization Osaka Medical Center for chronic cerebral infarction regenerative medicine products until March 31, 2029.38d ago K Pharma extended its joint research agreement with Kitasato Institute for hearing loss research until March 2027.38d ago K Pharma reported its Q2 FY2026 results on August 13, showing a narrowed net loss of 240 million yen for April-June, while the first-half cumulative net loss widened to 490 million yen.39d ago